Ardent: Solid Q1 and Reaffirmed 2026 Outlook Support Hold Rating as $12 Price Target Remains Unchanged

Ardent Health Partners, Inc., the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Craig Hettenbach from Morgan Stanley maintained a Hold rating on the stock and has a $12.00 price target.

Craig Hettenbach has given his Hold rating due to a combination of factors, including Ardent’s solid Q1 performance and the balance of risks looking forward. The company delivered better‑than‑expected revenue and EBITDA, supported by stronger pricing and improved cost efficiency, and management reaffirmed full‑year 2026 guidance, signaling confidence in the current trajectory.

However, the implied EBITDA outlook for the remainder of 2026 is below consensus despite the strong start, which tempers the near‑term upside potential. With revenue guidance essentially aligned with Street expectations and the stock already reflecting modest upside to the unchanged $12 price target, Hettenbach views the risk‑reward profile as balanced, supporting a Hold rather than a more aggressive rating.